Market Access | eMAX Health

Inside the Decision Room: How to Pressure-Test Your Value Story for Formulary Success

Inside the Decision Room: What Really Drives Formulary Placement Last week, we explored how payers are scrutinizing endpoints and comparators more closely than ever, and why validating your value story against payer expectations has become essential. But validation is...

How Payers Are Scrutinizing Endpoints and What Evidence Resonates Most in 2025

How Payers Are Scrutinizing Endpoints and What Evidence Resonates Most in 2025 For decades, pharmaceutical market access conversations revolved around price. Could a manufacturer justify a premium? Would contracting or rebates secure preferred placement? In 2025,...

The New Normal of Iterative Market Access: Why Static Annual Research is Dead

For years, pharmaceutical manufacturers relied on static research cycles. Advisory boards, annual payer interviews, and one-time market surveys shaped pricing, access, and contracting strategies. The strategy was to gather input once, align internally, and move...

A New Federal Healthcare Advisory Committee: Implications for Pharma Market Access

The Department of Health and Human Services (HHS) and the Centers for Medicare & Medicaid Services (CMS) recently announced the creation of a new Healthcare Advisory Committee—a body tasked with improving how care is financed and delivered under federal insurance...

MFN Deadline Is Here: How Pharma Teams Can Respond Strategically

𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗔𝗹𝗲𝗿𝘁: 𝗠𝗙𝗡 𝗗𝗲𝗮𝗱𝗹𝗶𝗻𝗲 𝗜𝘀 𝗛𝗲𝗿𝗲. 𝗜𝘀 𝗬𝗼𝘂𝗿 𝗧𝗲𝗮𝗺 𝗥𝗲𝗮𝗱𝘆 𝗳𝗼𝗿 𝗪𝗵𝗮𝘁 𝗖𝗼𝗺𝗲𝘀 𝗡𝗲𝘅𝘁? June 11 marks the end of the voluntary compliance window under the Most-Favored-Nation (MFN) Executive Order. If your organization hasn’t finalized a pricing strategy, the time for...

From Opinion to Precision: How Elasticity™ Aligns Pricing and Value Strategy

𝗬𝗼𝘂𝗿 𝗣𝗿𝗼𝗱𝘂𝗰𝘁’𝘀 𝗩𝗮𝗹𝘂𝗲 𝗜𝘀𝗻’𝘁 𝗦𝘁𝗮𝘁𝗶𝗰. 𝗦𝗼 𝗪𝗵𝘆 𝗜𝘀 𝗬𝗼𝘂𝗿 𝗣𝗿𝗶𝗰𝗶𝗻𝗴 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆? Imagine your Commercial and Medical teams are preparing for launch. You’ve got an asset with differentiated clinical value—but the price is still up for debate. The Commercial team needs to justify a...

« Older Entries

Inside the Decision Room: How to Pressure-Test Your Value Story for Formulary Success

How Payers Are Scrutinizing Endpoints and What Evidence Resonates Most in 2025

The New Normal of Iterative Market Access: Why Static Annual Research is Dead

A New Federal Healthcare Advisory Committee: Implications for Pharma Market Access

MFN Deadline Is Here: How Pharma Teams Can Respond Strategically

From Opinion to Precision: How Elasticity™ Aligns Pricing and Value Strategy

Search by Category:

Recent Posts:

Search by Keyword:

Inside the Decision Room: How to Pressure-Test Your Value Story for Formulary Success

How Payers Are Scrutinizing Endpoints and What Evidence Resonates Most in 2025

The New Normal of Iterative Market Access: Why Static Annual Research is Dead

A New Federal Healthcare Advisory Committee: Implications for Pharma Market Access

MFN Deadline Is Here: How Pharma Teams Can Respond Strategically

From Opinion to Precision: How Elasticity™ Aligns Pricing and Value Strategy

Search by Category:

Recent Posts:

Search by Keyword:

Cookie Consent

Your Privacy Choices

Strictly Necessary (Always Active)

Analytics & Performance

Marketing & Advertising